Novo Nordisk’s (NVO) Wegovy and Eli Lilly’s (LLY) Mounjaro had their prices lowered by British online pharmacies and slimming clinics as supply shortages ease after the drugs’ recent launch, Reuters reported Thursday.
Rising competition among retailers for weight-loss drugs increases risks of patients losing long-term care by switching providers, rather than relying on the National Health Service. Self-paying patients drive significant revenue for Wegovy and Mounjaro, the report said.
Analysts foresee a potential $100 billion annual market for these drugs, prompting aggressive efforts by drug retailers to attract customers, Reuters said.
Lilly told Reuters that it has not adjusted its prices, while Novo explained that pricing is determined by the providers delivering the drugs to patients. The NHS didn’t respond to Reuters’ request for comment.